Articles from BPGbio

Recognition highlights Narain’s impact in AI-driven drug discovery and biology-first innovation to the biopharma industry

Advanced Spatial Quinomics Study Reveals Novel Insights into the Therapeutic Impact of BPM31510, Being Studied as a Potential Treatment for Primary CoQ10 Deficiency and Other Mitochondrial Diseases

Company’s presentations highlight the power of mitochondrial medicine and protein homeostasis technologies to address aggressive cancers including glioblastoma and pancreatic cancer

BPGbio, a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, is thrilled to announce its contribution to a groundbreaking study published in the January 10 issue of Science. This study describes the discovery of a novel lipid-rich tissue type, lipocartilage, which exhibits unique skeletal support properties distinct from classical cartilage rich in extracellular matrix proteins. This discovery has transformative implications for regenerative medicine and reconstructive surgery, offering new pathways for personalized cartilage tissue repair and replacement.

BPGbio, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, announced today the publication of a significant, multi-year research effort titled “Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel” in Scientific Reports.